Grifols: starts human trials for Covid-19 plasma treatment
(CercleFinance.com) - Spain's Grifols on Friday said it has started human clinical trials for a potential plasma-derived treatment of Covid-19.
The Barcelona-based firm said that its anti-SARS-CoV-2 hyperimmune globulin has started a randomised controlled clinical study to test its safety, efficacy and tolerability.
This phase 3 trial will include 500 hospitalised adults with Covid-19 in up to 58 hospitals covering 18 countries, including the United States and Spain, it said.
The therapy - which comes from the convalescent plasma of healthy people who have recovered from the disease - could be used for both prevention and treatment of the disease, Grifols added.
The clinical trial is part of a collaboration with several US government agencies such as the Food and Drug Administration (FDA) and the NIH, the US government's premier health-research agency.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Barcelona-based firm said that its anti-SARS-CoV-2 hyperimmune globulin has started a randomised controlled clinical study to test its safety, efficacy and tolerability.
This phase 3 trial will include 500 hospitalised adults with Covid-19 in up to 58 hospitals covering 18 countries, including the United States and Spain, it said.
The therapy - which comes from the convalescent plasma of healthy people who have recovered from the disease - could be used for both prevention and treatment of the disease, Grifols added.
The clinical trial is part of a collaboration with several US government agencies such as the Food and Drug Administration (FDA) and the NIH, the US government's premier health-research agency.
Copyright (c) 2020 CercleFinance.com. All rights reserved.